© Copyright Acquisition International 2026 - All Rights Reserved.

Article Image - Avant Diagnostics and Amarantus Diagnostics to Combine with Theranostics Health
Posted 7th March 2016

Avant Diagnostics and Amarantus Diagnostics to Combine with Theranostics Health

Avant Diagnostics, Inc, a biotechnology company focused on the development of oncology based diagnostics, and Amarantus Diagnostics, Inc, a wholly-owned subsidiary of Amarantus BioScience Holdings, Inc, today announced that the companies have jointly entered into a letter of intent for Avant to acqu

Mouse Scroll AnimationScroll to keep reading

Let us help promote your business to a wider following.

Avant Diagnostics and Amarantus Diagnostics to Combine with Theranostics Health
Image

Avant Diagnostics, Inc., a biotechnology company focused on the development of oncology based diagnostics, and Amarantus Diagnostics, Inc, a wholly-owned subsidiary of Amarantus BioScience Holdings, Inc, today announced that the companies have jointly entered into a letter of intent for Avant to acquire assets and certain liabilities of Theranostics Health Incorporated, adding key CLIA laboratory and intellectual property capabilities to Avant’s previously announced letter of intent to merge with Amarantus Diagnostics (collectively, the “Transactions”).

THI currently generates over $1.5M in services revenue from some of the world’s leading biopharmaceutical companies, including 7 of the top 10 pharmaceutical companies by revenue. The companies will be holding a conference call to discuss the business combination today at 4:30 PM ET. To access the conference call please dial 215-383-1625 or toll free 800-356-8278; access code 135394.

Under the terms of the letter of intent, Avant shall issue to THI 25 million shares of its common stock upon the closing. Amarantus BioScience has provided a convertible note of $400,000 to THI to facilitate the transaction that will be assumed by Avant upon closing of the transactions. As previously disclosed, Avant plans to issue 80 million shares of its common stock to Amarantus Biosciences upon completion of its merger with Amarantus Diagnostics. The Transactions are expected to close in the first half of 2016, and are subject to customary closing conditions.

Gerald E. Commissiong, President & CEO of Amarantus said:

“THI is a leader in the area of signal transduction biology, where they have been able to attract an A-list of pharmaceutical customers collaborating with the company to evaluate the therapeutic benefit and potential of their drug candidates using THI’s proprietary assays.

“In addition, THI has a CLIA lab where Amarantus’ Diagnostics has established operations over the course of the first quarter that will allow for CLIA validation and commercial launch of the combined company’s suite of high-value, proprietary diagnostics in the areas of oncology and neurology. THI’s sales channel into the pharmaceutical industry will provide important leverage for the combined company to market the LymPro Test® for Alzheimer’s disease. We could not have picked a better partner to bring Avant and Amarantus’ Diagnostics leading-edge intellectual property in diagnostics and biomarkers to the market.”

Gregg Linn, President & CEO of Avant Diagnostics added:

“Key to the business case for the merged company is THI’s impressive pharma services revenue base and sales channel in the area of cell signaling biology. In addition to this, THI’s CLIA laboratory provides the combined company with the infrastructure to launch OvaDx®, MSPrecise® and LymPro Test in a regulatory compliant environment that has been vetted by some of the world’s top pharmaceutical companies. THI’s laboratory meets the highest quality standards under CLIA/CAP which should give both our pharmaceutical and commercial customers great confidence in the information generated in THI’s laboratory.”

THI’s core business is centred on providing pharmaceutical and biotechnical companies access to its technology for quantitatively measuring the activation status of key proteins and signal transduction pathways that are dysregulated in multiple disease processes via its Reverse-phase Protein Array (RPPA) platform. THI is experienced in running CAP-accredited assays in its CLIA laboratory for predicting response to therapies in difficult to treat cancers.  THI believes that, while genomic approaches may identify potential activating mutations in diseased tissues, measuring the actual activation status of the protein drug targets and the signal transduction pathways that they regulate, provides physicians with much-needed evidence that a particular therapeutic strategy can provide benefits to the patient.  THI has launched tests, TheraLink® Assays, for guiding therapeutic decisions in breast and colorectal cancer. The post-merger Avant Diagnostics will further build on its recognized scientific expertise in the area of cell cycle biology to increase its pharma services revenues and provide therapy guiding diagnostics in difficult to treat conditions.

Glenn Hoke, PhD, Chief Executive Officer of THI added:

“After an extensive evaluation of the diagnostics market, we believe that we have found the best potential partners in Avant and Amarantus. It is clear that we will be expanding our CLIA offerings with much needed tests such as OvaDx in cancer and MSPrecise in neurology, while also providing significant additional pharma services business development opportunities with the LymPro Test. With platforms in microarray proteomics, ELISA, flow cytometry and ‘next-gen’ sequencing, the combined company’s capabilities will allow it to add cross-platform diagnostics as we grow into the future.”

 

 

Categories: Innovation, M&A, Strategy


You Might Also Like
Read Full PostRead - Eye Icon
New Challenges for Telecoms M&A in Digital Markets
M&A
25/11/2015New Challenges for Telecoms M&A in Digital Markets

The challenges facing telecom service providers seeking mergers and acquisitions in the converging digital market place is a key theme at this year's TMT Finance World Congress in London.

Read Full PostRead - Eye Icon
Driven by Success: Auto Europe Group – Imad Khalidi CEO of the Month: USA
Leadership
05/07/2016Driven by Success: Auto Europe Group – Imad Khalidi CEO of the Month: USA

For over half a century, Auto Europe has been a leader in worldwide car rental services.

Read Full PostRead - Eye Icon
What Are Commercial Cross-Border Disputes and How Can You Resolve Them?
Legal
12/01/2023What Are Commercial Cross-Border Disputes and How Can You Resolve Them?

A legal dispute of any kind can be stressful and damaging for each party involved, more so when a claim is brought against your business in a cross-border dispute. At the very minimum, there will be two jurisdictions and various international laws to contend w

Read Full PostRead - Eye Icon
Adapting to a Volatile Trading Market in 2022
Finance
15/06/2022Adapting to a Volatile Trading Market in 2022

Volatility is a common part of the trading landscape for experienced investors, but it’s still something many struggle with when it comes to securing and managing their portfolio. The transition from 2021 and 2022 has been a complex one for new investors and

Read Full PostRead - Eye Icon
Factors to Consider Before Applying for a Loan
News
04/09/2023Factors to Consider Before Applying for a Loan

Image on Unsplash A personal loan can swiftly provide you with financial resources that you can utilize for nearly any purpose. You might resort to personal loans to cover unexpected costs, merge debt from credit cards with higher interest rates, or fund acqui

Read Full PostRead - Eye Icon
Proud to Support its Veterans
News
05/10/2022Proud to Support its Veterans

Woodside Quality LLC (Woodside) is a CVE Certified Service-Disabled Veteran Owned Small Business (SDVOSB) providing performance improvement, project management, and analytics support to federal and commercial clients.

Read Full PostRead - Eye Icon
New 3D Approach to Engaging Research
Innovation
12/11/2015New 3D Approach to Engaging Research

A new research tool, Voxter, has been launched in London as an innovative, 3D communication solution for meaningful research.

Read Full PostRead - Eye Icon
7 Considerations to Keep in Mind When Downsizing Your Office Space
News
16/09/20227 Considerations to Keep in Mind When Downsizing Your Office Space

The process of downsizing your office space can be daunting, but it doesn't have to be. A lot of companies right now have decided to downsize their office space for a variety of reasons. Maybe your company is doing better than expected and you're running out o

Read Full PostRead - Eye Icon
Reshaping Business Communication Strategies for The Post-Covid Landscape
Innovation
02/11/2020Reshaping Business Communication Strategies for The Post-Covid Landscape

Rapid and major shifts in the economic and social landscape in the wake of Covid-19 are fundamentally changing the nature of interactions and relationships among enterprises and individuals. Business leaders, therefore, are now determining how enabling technol



Our Trusted Brands

Acquisition International is a flagship brand of AI Global Media. AI Global Media is a B2B enterprise and are committed to creating engaging content allowing businesses to market their services to a larger global audience. We have a number of unique brands, each of which serves a specific industry or region. Each brand covers the latest news in its sector and publishes a digital magazine and newsletter which is read by a global audience.

Arrow